PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION

The incidence of chronic hepatitis C inRussiais extremely high, that requires an increase the access to effective treatment regimens.The aim of the study is to assess the cost of HCV therapy (genotype 1) of naïve patients without cirrhosis with second wave protease inhibitors narlaprevir and simepre...

Full description

Bibliographic Details
Main Authors: A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Format: Article
Language:Russian
Published: Journal Infectology 2017-04-01
Series:Žurnal Infektologii
Subjects:
chronic hepatitis c
naive patients
simeprevir
narlaprevir
cost
Online Access:https://journal.niidi.ru/jofin/article/view/568

Internet

https://journal.niidi.ru/jofin/article/view/568

Similar Items